BC Week In Review | Sep 15, 2014
Clinical News

CINtec p16 Histology test regulatory update

Roche's Ventana Medical Systems Inc. unit said the World Health Organization (WHO) issued guidance recommending the use of cyclin dependent kinase inhibitor 2A ( CDKN2A ; INK4a ; ARF; p16INK4a ) immunohistochemistry (IHC) testing to improve the...
BC Week In Review | Jul 25, 2011
Company News

mtm, Roche deal

Roche will acquire cervical cancer diagnostic company mtm for about €130 million ($182.6 million) in cash and up to an additional €60 million ($84 million) in milestones. mtm will become part of Roche's tissue diagnostic...
BC Extra | Jul 20, 2011
Company News

Roche to acquire mtm

Roche (SIX:ROG; OTCQX:RHHBY) will acquire cervical cancer diagnostic company mtm laboratories AG (Heidelberg, Germany) for about EUR 130 million ($182.6 million) in cash and up to an additional EUR 60 million ($84 million) in milestones....
BC Week In Review | Mar 1, 2010
Clinical News

CINtec Histology Kit: Pivotal trial data

Data from a European pivotal trial showed that mtm's CINtec Histology p16 Histology Kit in conjunction with conventional H&E-stained cervical biopsy specimens met the primary endpoint of significantly increased accuracy vs. slides stained with H&E...
BC Week In Review | Jan 8, 2007
Company News

mtm sales and marketing update

mtm launched its CINtec Histology Kit and CINtec Cytology Kit for diagnosing cervical cancer in vitro. The kits detect overexpression of p16INK4a in cervical biopsies and cytology preparations. In order to commercialize its CINtec diagnostic...
Items per page:
1 - 5 of 5